stockrow
Friday 6 November 2026
Export ZYME’s income statement to Excel — free account
Zymeworks Inc.
ZYME Healthcare Biotechnology
Zymeworks Inc.’s revenue for fiscal 2025 (year ended December 2025) was $106.0 million, up 38.9% from fiscal 2024.
- Revenue
- −90.6%
- EPS
- −2,166.7%
- Free cash flow
- −385.5%
Quarter to June 2026, against a year earlier
29.52
0.78
+2.71%
Follow ZYME
Alert me
Zymeworks Inc. (ZYME) Net income
Zymeworks Inc.'s net income for fiscal 2025 was −$81.1M, compared with −$122.7M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$150.0M. Over the past ten years it has ranged from −$211.8M (fiscal 2021) to $124.3M (fiscal 2022); the current reading is higher than 55% of that period. Zymeworks Inc. ranks 480th of 605 Biotechnology companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | −$81.1M | — |
| FY2024 | −$122.7M | — |
| FY2023 | −$118.7M | — |
| FY2022 | $124.3M | — |
| FY2021 | −$211.8M | — |
| FY2020 | −$180.6M | — |
| FY2019 | −$145.4M | — |
| FY2018 | −$36.6M | — |
| FY2017 | −$10.4M | — |
| FY2016 | −$33.8M | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Jun 2026 | −$45.0M | — |
| Mar 2026 | −$44.2M | — |
| Dec 2025 | −$41.2M | — |
| Sep 2025 | −$19.6M | — |
| 39 more quarters | Free account |
Against its own ten years
Low −$211.8M
High $124.3M
Ten-year median
−$81.1M
Current reading's percentile
55
Net income against peers
| Company | Net income |
|---|---|
| AUPH Aurinia Pharmaceuticals Inc compare | $314.3M |
| VCEL Vericel Corporation compare | $33.3M |
| SEPN Septerna, Inc. compare | −$24.2M |
| COAG Hemab Therapeutics Holdings, Inc. compare | −$59.0M |
| ZYME Zymeworks Inc. | −$150.0M |
| IMNM Immunome, Inc. compare | −$254.3M |
| VERA Vera Therapeutics, Inc. compare | −$401.9M |
| BHVN Biohaven Ltd. compare | −$542.7M |
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | −$652.4M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on ZYME
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement